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Most iron in mammalian systems is routed to mitochondria to serve as a substrate for ferrochelatase. Ferrochelatase inserts iron into
protoporphyrin IX to form heme which is incorporated into hemoglobin and cytochromes, the dominant hemoproteins in mammals. Tissue-
specific regulatory features characterize the heme biosynthetic pathway. In erythroid cells, regulation is mediated by erythroid-specific
transcription factors and the availability of iron as Fe/S clusters. In non-erythroid cells the pathway is regulated by heme-mediated feedback
inhibition. All of the enzymes in the heme biosynthetic pathway have been crystallized and the crystal structures have permitted detailed analyses
of enzyme mechanisms. All of the genes encoding the heme biosynthetic enzymes have been cloned and mutations of these genes are responsible
for a group of human disorders designated the porphyrias and for X-linked sideroblastic anemia. The biochemistry, structural biology and the
mechanisms of tissue-specific regulation are presented in this review along with the key features of the porphyric disorders.
© 2006 Elsevier B.V. All rights reserved.Keywords: Iron; Heme; Porphyrin; Porphyrias1. Introduction
The total body iron content in adult humans is approximately
50 mg/kg in men and 40 mg/kg in women [1]. Almost all iron is
incorporated into heme-containing proteins, particularly hemo-
globin, myoglobin and cytochromes. The gender-based differ-
ence in body iron content is due to the smaller red cell, muscle
and liver mass in women. The unique properties of heme, an
iron molecule coordinated within a tetrapyrrole, allows heme to
function both as an electron carrier and a catalyst for redox
reactions. Heme is generated by the insertion of ferrous iron into
the tetrapyrrole macrocycle of protoporphyrin IX, a reaction
catalyzed by ferrochelatase, which resides in the mitochondrial
matrix (Fig. 1). A highly conserved pathway involving both
cytosolic and mitochondrial compartments is utilized to
generate protoporphyrin IX but all of the heme biosynthetic
genes are nuclear-encoded and translated in the cytoplasm.
Most heme synthesis takes place in developing red cells in
the marrow but about 15% of the daily production takes place in
the liver for the formation of heme-containing enzymes. The
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over rapidly, enabling the liver to respond to changing
metabolic requirements. In erythroid progenitors, however, the
pathway is regulated to permit a high steady-state level of heme
synthesis and regulation is tied to the availability of iron. There
are both “housekeeping” and erythroid genes for aminole-
vulinate synthase, the first and rate-limiting enzyme in the
pathway and the next three genes have dual promoters allowing
both erythroid-specific and non-erythroid regulation [2]. The
remaining genes in the pathway have single promoters but
nevertheless exhibit erythroid and non-erythroid expression
differences. These differences will be discussed for each en-
zyme in the pathway.
Heme biosynthetic enzymes have been intensively studied in
recent years. All of the genes involved have been cloned and the
crystal structures of all of the enzymes have been determined. In
this review we will dissect the complex heme biosynthetic
pathway into four basic processes:
(1) Formation of the pyrrole.
(2) Assembly of the tetrapyrrole.
(3) Modification of the tetrapyrrole side chains.
(4) Oxidation of protoporphyrinogen IX to protoporphyrin
IX and insertion of iron.
Fig. 1. The heme biosynthetic pathway. Mitochondrial enzymes are depicted in green and cytosolic enzymes in red. Abbreviations used in the text are capitalized.
Table 1
Clinical features of the porphyrias
Photosensitivity only Neurovisceral attacks and
photosensitivity
Neurovisceral
attacks only
Congenital
erythropoietic porphyria
Hereditary coproporphyria Acute intermittent
porphyria
Porphyria cutanea tarda Variegate porphyria ALAD porphyria
Erythropoietic porphyria
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the pathway and lead to diseases including X-linked sideroblastic
anemia, lead poisoning and the porphyrias. The porphyrias
represent a group of disorders characterized by either acute
neurovisceral attacks or photosensitivity and sometimes both.
Accumulated substrates of defective pathway enzymes are
responsible for disease symptoms. Compelling evidence has
been generated indicating that neurovisceral symptoms are due to
neurotoxic affects of porphyrin precursors. The photosensitivity
is due to the fluorescent properties of porphyrins. A convenient
way to classify the porphyrias is to divide them according to the
dominant clinical feature (Table 1), although some authors prefer
to divide the porphyrias based on whether excess substrate is
generated in the liver (hepatic porphyrias) or the red cell
(erythropoietic porphyrias). Here, each porphyric disorder will be
described in the context of the step in the pathway which is
defective.
1.1. Formation of the pyrrole
The first and rate-limiting reaction in the pathway is a
condensation reaction between glycine and succinyl-CoA toform 5-aminolevulinic acid (ALA) (Fig. 2A). The reaction is
catalyzed by two different ALA synthases, one expressed
ubiquitously (ALAS1) and the other expressed only erythroid
precursors (ALAS2). The gene encoding ALAS1 maps to the
short arm of chromosome 3 [3] whereas ALAS2 is encoded on
the X chromosome [4]. Regulation of these two forms of ALAS
is mediated by different mechanisms but both forms require
pyridoxal 5-phosphate (PLP) as a cofactor (Fig. 2B) and both
are expressed as homodimers. PLP binds to a specific lysine of
ALAS. A PLP-glycine Schiff base complex is then formed
which reacts with succinyl-CoA. The crystal structure of ALAS
from Rhodobacter capsulatus, which is highly homologous to
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contain an amino terminal mitochondrial targeting sequence
which also contains a heme-binding motif. There are two
putative heme-binding motifs (HRM) in the N-terminal
mitochondrial targeting domain and a third in the N-terminus
of the mature protein [6]. Binding of heme to this motif blocksmitochondrial import, representing a post-translation point of
end-product feedback inhibition of the pathway. One study
suggested that the heme-binding motif is functional only in
ALAS1 [7]. Systematic mutations of the three HRMs suggested
that HRM1 and HRM3 contributed to heme-dependent
inhibition of mitochondrial transport, but HRM2 did not.
Under the same experimental conditions, ALAS2 import was
not inhibited by exogenous hemin. A different study found that
any one of the three ALAS1 HRMs was sufficient to obtain
heme-dependent inhibition of mitochondrial transport [8].
ALAS2 was not examined.
Both forms of ALAS are transcriptionally regulated but by
quite different mechanisms [9–11]. In addition to heme's post-
translational affect on mitochondrial import, heme down-
regulates transcription of ALAS1. In humans there are two
alternate splice forms of ALAS1. The major form lacks exon 1B
(Fig. 4) and is subject to heme-mediated destabilization [9,12].
The minor form contains exon 1B and is resistant to heme-
mediated decay and may require translation for destabilization
in response to heme [13]. Transcription of ALAS1 is
upregulated by the peroxisome proliferator-activated coactivator
1α (PGC-1α) [14]. PGC-1α is a coactivator of nuclear receptors
and transcription factors [15]. The effects of PGC-1α are
mediated by interactions with NRF-1 (nuclear regulatory factor
1) and FOX01 (a fork head family member) with the ALAS1
promoter [16]. Transcription of PCG-1α is upregulated when
cellular glucose levels are low [17,18]. Upregulation of PGC-1α
leads to increased levels of ALAS1, creating conditions capable
of precipitating attacks of the neurovisceral porphyrias (see
below). This is probably the explanation for the clinical
observation that fasting may precipitate attacks whereas glucose
infusions may attenuate the severity of attacks [19,20].
In contrast to ALAS1, transcriptional regulation of ALAS2 is
mediated by erythroid-specific factors (including GATA1)
which interact with sequences in the promoter region,
sequences contained in many genes differentially regulated in
red cells [10]. Translational regulation also plays an important
role in determining ALAS2 expression. The ALAS2 transcript
contains a 5′ iron regulatory element (IRE) which interacts with
an IRE binding protein (IRP). The IRE–IRP complex prevents
translation of the ALAS2 mRNA. Addition of an iron–sulfur
cluster (Fe/S) abolishes the ability of IRPs to bind to the IRE
and permits translation to occur. Fe/S clusters are generated and
exported by mitochondria, linking regulation of heme biosyn-
thesis in the red cell to iron availability and mitochondrial
function [21–23].Fig. 2. (A) Synthesis of 5-aminolevulinic acid (ALA). Decarboxylation of
glycine followed by condensation with Succinyl-CoA is catalyzed by
aminolevulinic acid synthase (ALAS). Pyridoxal Phosphate is required as a
co-factor. The products are ALA, CO2 and CoA. (B) The crystal structure of the
active site of R. capsulatusALAS [5]. Pyridoxal Phosphate (PLP) (fuchsia), first
forms a covalent linkage with lysine (lys 391 in human ALAS). Incoming
glycine induces a transient trans-aldimine (Schiff base) with PLP binding
glycine rather than lysine. Succinyl-CoA (green) is condensed with the α carbon
of glycine with the displacement of CoA (green) and the carboxyl group of
glycine (yellow and red). ALA is released and PLP rebinds to the lysine of
ALAS.
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nized in humans. Mutations in ALAS2, however, are causative
for X-linked sideroblastic anemia (XLSA). The disorder is
characterized by a microcytic hypochromic anemia and the
presence of iron-laden mitochondria encircling the nucleus of
developing red cells in the marrow (ringed sideroblasts). The
clinical features of XLSA have been well described in recent
reviews [24]. Many, but not all patients with XLSA improve
with the administration of a pharmacologic dose of pyridoxine
and XLSA is often referred to as pyridoxine-responsive anemia
[25]. Forty-two point mutations affecting 37 residues of ALAS2
have been reported [5]. These mutations have been mapped in
the crystal structure of the highly homologous ALAS of R.
capsulatus [5]. Some directly affect the affinity of the enzyme
for the PLP cofactor and are associated with pyridoxine
responsiveness. Others affect domains not involved in cofactor
binding and are found in cases not responsive to pyridoxine.
Other rare forms of hereditary sideroblastic anemia have been
associated with defects in Fe/S cluster formation, mitochondrial
oxidative phosphorylation and thiamine metabolism. These
disorders have been recently reviewed [24].
Following its synthesis, ALA exits the mitochondria by an
unknown mechanism. Once in the cytosol, two molecules of
ALA form the monopyrrole porphobilinogen by a condensation
reaction catalyzed by aminolevulinate dehydratase (ALAD)
(Fig. 3). The crystal structure of human ALAD has been
determined [26,27]. The enzyme is a tetramer of homodimers
formed from eight identical subunits with one active site per
dimer [28]. The enzyme binds eight zinc atoms, one per subunit,
and ALAD is inactivated by reversible replacement of zinc by
lead. Four zinc molecules are essential for catalysis, whereas the
other four serve to stabilize the tertiary structure of the enzyme
[29–31]. Each active site binds two molecules of ALA at two
distinct positions. One molecule contributes the acetate and the
amino-methyl group of porphobilinogen (PBG). The other
molecule of ALA contributes the propionate side chain and the
pyrrole nitrogen (Fig. 3). In all tissues the activity of ALAD
greatly exceeds the activity of ALAS.Fig. 3. Synthesis of porphobilinogen (PBG). Two molecules of ALA (blue and o
aminolevulinic acid dehydratase (ALAD).In contrast to ALAS, there is only a single ALAD gene in
humans, located on chromosome 9q34 [32], which consists of
two alternatively spliced non-coding exons (1A and 1B) and
eleven coding exons (Fig. 4) [33]. The translational start site
(ATG) is located in exon 2. A “housekeeping” promoter is
located upstream from exon 1A. A second erythroid-specific
promoter is located between exons 1A and 1B. The erythroid-
specific promoter contains several binding sites for erythroid-
specific transcription factors including GATA1 [33]. The
housekeeping and erythroid transcripts differ, but both encode
identical proteins because they share the same translational start
site located in exon 2.
There are three disorders in humans associated with
deficiency of ALAD; hepatorenal tyrosinemia, ALAD por-
phyria and lead poisoning. Only ALAD porphyria is due to
mutations of the ALAD gene. Hepatorenal tyrosinemia is an
autosomal recessive disorder due to mutations of the fumary-
lacetoacetate hydrolase gene resulting in a defect in the last
step in tyrosine catabolism, the hydrolysis of fumarylacetoa-
cetate to fumarate and acetoacetate [34]. In the absence of
enzyme activity, fumarylacetoacetate is subsequently metab-
olized to succinylacetoacetic acid and succinylacetone.
Hypertyrosinemia is present in all patients but the presence
of high levels of succinylacetone in plasma or urine is
diagnostic for this disorder. Clinical manifestations include
abnormalities of the liver, kidney and nerves. One of the most
striking features is intermittent, painful neurological crises
quite similar to the neurovisceral attacks associated with the
acute porphyrias (see below). Succinylacetone is a potent
inhibitor of ALAD [35]. Structurally, succinylacetone closely
resembles ALA and acts as a competitive inhibitor of ALAD.
ALAD activity in the liver and erythroid precursors is
dramatically reduced and excess ALA is excreted in the urine.
It has been proposed that ALA is neurotoxic and is the cause
of the neurologic crises in patients with hepatorenal
tyrosinemia [34]. Liver transplantation has proven to be
curative for all of the clinical manifestations of hepatorenal
tyrosinemia.range) are condensed to form PBG, a monopyrrole, by the cytosolic enzyme
Fig. 4. Tissue-specific expression of the “early” genes in the heme biosynthetic
pathway. =Housekeeping promoter. =Erythroid promoter. Chr.=chromo-
some location. ATG=translational start site. ATG-C=Common transcriptional
start site. ATG-H=Housekeeping transcriptional start site. ATG-E=Erythroid
transcriptional start site. The single genes for ALAD, PBGD and URO3S utilize
tissue-specific promoters and alternative splicing to generate either identical
proteins (ALAD, URO3S) or tissue-specific proteins (PBGD).
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to mutations of the ALAD gene [2]. Fewer than ten cases have
been reported. ALAD activity in both the liver and erythroid
precursors is markedly deficient leading to the accumulation
and urinary excretion of ALA. The clinical manifestations have
varied from case to case but most affected individuals have had
intermittent acute neurovisceral attacks resembling those seen
in patients with other acute porphyrias. In contrast to
hepatorenal tyrosinemia, liver transplantation has not proven
beneficial in the one patient in whom transplantation was
performed. After transplantation, increased excretion of ALA
in the urine persisted, suggesting that extra-hepatic generation
of ALA was sufficient to sustain the clinical manifestations
[36].
Lead inhibits ALAD activity by displacing zinc atoms from
the enzyme, resulting in high concentrations of ALA in blood
and urine [2]. Lead in plasma is taken up by red cells and is
bound to ALAD. Patients with lead poisoning often develop
neurologic manifestations resembling those found in the acute
porphyrias. It has been suggested that the elevated concentra-
tions of ALA are responsible for the neurologic symptoms but
lead itself may have toxic effects on the nervous system. A
common ALAD polymorphism (K59N) results in an enzyme
that has a higher affinity for zinc and thus a lower ability to bind
lead. The result is higher plasma lead levels in subjects with the
K59N allele. This may facilitate delivery of lead to the nervous
system and explain the association of the K59N allele with an
increased risk for lead intoxication [37].
1.2. Formation of the tetrapyrrole macrocycle
A polymer of four molecules of PBG is generated in the
cytosol by porphobilinogen deaminase (PBGD). The polymer is
an unstable tetrapyrrole designated hydroxymethylbilane(HMB) (Fig. 5A). PBGD functions as a monomer and the
crystal structure has been determined [38]. Purification of
PBGD from mammals and bacteria yields an enzyme with a
dipyrrole (dipyrromethane) cofactor in the catalytic site. The
dipyrrole is derived by a novel mechanism. PBGD first binds
HMB and then deaminates and polymerizes two additional
molecules of PBG to form a hexapyrrole. The final step is
cleavage of the distal tetrapyrrole and the release of HMB. The
proximal dipyrrole remains covalently bound to the enzyme and
is not turned over (Fig. 5B) [39].
The human PBGD gene has been cloned and mapped to
chromosome 11q23-11qter [40]. The gene contains 15 exons. As
with the ALAD gene, two separate promoters control transcrip-
tion (Fig. 4). The housekeeping promoter lies upstream of exon 1
and the erythroid promoter lies upstream of exon 2. Transcrip-
tion initiated by the housekeeping promoter results in a transcript
in which exon 2 is lost by splicing of exon 1 to exon 3.
Transcription initiated by the erythroid promoter results in a
transcript containing exons 2–15. The erythroid promoter
resembles other erythroid-specific promoters [41]. Translation
of the erythroid mRNA is initiated at an AUG located in exon 3
(exon 2 lacks an AUG) [42]. The AUG translational start site
encoded in exon 1 of the housekeeping transcript is spliced in-
frame with the AUG in exon 3 and produces a protein 17 amino
acids longer at the amino terminus compared to the erythroid
protein [43].
Acute intermittent porphyria (AIP) is caused by mutations of
the PBGD gene. Over 200 PBGD mutations have been detected
[19]. The disorder is transmitted as an autosomal dominant trait,
but the majority of heterozygotes for gene mutations remain
asymptomatic. In Europe, acute attacks of porphyria occur with
a frequency of approximately 1–2 per 100,000. A study of blood
donors in France produced an estimate of gene frequency of at
least 1:1675 suggesting that the clinical penetrance is low
[44,45]. Others may have only one or a few neurovisceral attacks
throughout life. Acute attacks usually occur after puberty, but in
rare cases of homozygosity or compound heterozygosity for
PBGD mutations, severe attacks may begin in childhood. In
heterozygotes, acute attacks are often precipitated by exposure
to drugs metabolized by cytochrome P450 enzymes. Induction
of these enzymes depletes hepatic heme leading to the induction
of ALAS. Caloric deprivation may also precipitate acute attacks
and glucose infusions may attenuate or even abort attacks. The
mechanism mediating the effects of caloric restriction and
glucose infusions has been discussed above and is related to
transcriptional regulation of the peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α) by glucose
availability. When cellular glucose levels are low, PGC-1 α
production increases, leading to increased levels of ALAS1.
This in turn increases levels of PBG, the substrate of PBGD.
When cellular glucose is replete, PGC-1 α is suppressed and
ALAS1 transcription is diminished. The preferred, and most
effective treatment for acute attacks is the intravenous
administration of hematin which downregulates ALAS I. During
acute attacks urinary excretion of ALA and PBG is markedly
increased. Hepatic overproduction of these porphyrin precursors
is causative for the neurologic symptoms. In support of this
Fig. 5. (A) Synthesis of hydroxymethylbilane (HMB). The reaction is catalyzed by the cytosolic enzyme porphobilinogen deaminase (PBGD). A dipyrromethane
cofactor (DPM) is covalently bound to the enzyme in the catalytic site. Four additional molecules of PBG are deaminated and polymerized to form a hexapyrrole. The
distal tetrapyrrole is then cleaved and released as HMB. (B) The crystal structure of a human PBGD monomer is shown with the dipyrromethane cofactor (green)
bound in the catalytic site.
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tion in a young woman with disabling acute attacks resulted in
normalization of urinary ALA and PBG levels within a day and
completely eliminated her recurrent attacks [46].
The product of the PBGD reaction, HMB, serves as the
substrate for uroporphyrinogen III synthase (URO3S). URO3S
catalyzes the conversion of HMB to uroporphyrinogen III
(URO'GEN III) by inversion of the D-ring of HMB followed
by closure of the tetrapyrrole macrocycle (Fig. 6). Spontaneous
cyclization of HMB can also occur, but the product, URO'GEN I,
cannot ultimately be converted to heme. The crystal structure of
human URO3S has been determined [47]. The enzyme functions
as a monomer. There is a single URO3S gene in humans which
encodes 10 exons [48] and is localized to chromosome 10q25.2–
26.3 (Fig. 4) [49]. The ATG translational start site is encoded
within exon 2B. As with ALAD and PBGD, both non-erythroid
and erythroid-specific transcripts are produced. An erythroid-
specific promoter within intron 1 contains 8 GATA1 binding sites.
The erythroid-specific mRNA contains all of exon 2. The non-
erythroid promoter lies upstream of exon 1 and contains binding
sites for Sp1, NF1, AP1 Oct1 and NRF2 [50]. The promoter
region lacks a TATA box. The ubiquitously expressed non-erythroid transcript results from a splicing event that joins exon 1
to exon 2B which contains the ATG start site. Although the non-
erythroid and erythroid-specific transcripts are expressed from
alternative promoters, both produce the identical protein.
Mutations of URO3S are responsible for a rare form of
porphyria in humans designated congenital erythropoietic
porphyria (CEP) [2]. CEP is transmitted as an autosomal
recessive trait. Markedly diminished URO3S activity results in
the accumulation of uroporphyrin I (URO I) in erythrocytes.
Diffusion of URO I to plasma mediates the photo-mutilation
characteristic of CEP. In most cases, cutaneous photosensitivity
begins in early infancy and eventually leads to cutaneous
scarring and deformities. Most patients with CEP have less than
10% of normal erythrocyte URO3S activity [51]. Heterozygous
carriers of URO3S mutations have no phenotype. Patients with
CEP are either homozygous for a single URO3S mutation or are
compound heterozygotes. Over twenty URO3S mutations have
been described including missense and nonsense mutations,
large and small deletions, splicing defects and intronic branch-
point mutations [52]. A recent report described a patient with
CEP in whom there were no URO3S mutations [53]. A
mutation of GATA1, an erythroid-specific transcription factor
Fig. 6. Synthesis of uroporphyrinogen III (URO'GEN III). The reaction is catalyzed by the cytosolic enzyme uroporphyrinogen III synthase (URO3S). The enzyme
catalyzes ring closure of hydroxymethylbilane (HMB) with concurrent “flipping” of the D ring to generate uroporphyrinogen III (URO'GEN III). The D ring acetate
group is in red and the propionate is in blue.
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not affected and there was only a modest reduction in
expression of ALAD. These findings suggest that erythroid-
specific promoters are not all functionally equivalent.
1.3. Modification of the acetate and propionate side chains
URO'GEN III represents a branch point for the pathways
leading to heme, chlorophyll and corrins (polyaromatic rings
related to porphyrins). In the heme biosynthetic pathway,
URO'GEN III is converted to coproporphyrinogen III
(COPRO'GEN III) by the sequential removal of the four
carboxylic groups of the acetic acid side chains, a reaction
catalyzed by uroporphyrinogen decarboxylase (UROD) (Fig.
7A) [54]. URO'GEN III is the preferred substrate. URO'GEN I
can also be decarboxylated but only COPRO'GEN III can be
converted to protoporphyrin IX. Decarboxylation of URO'GEN
III begins at the asymmetric D-ring and proceeds in a clockwise
manner [55]. The crystal structure of human UROD has been
determined [56]. The enzymes functions as a homodimer and
each monomer contains an active site cleft. Structural studies of
the active site indicate that only the flexible porphyrinogen
macrocycle can be accommodated (Fig. 7B) [57]. The rigid,
planar porphyrin molecule is not a substrate.
There is a single human UROD gene located on chromosome
1p34 [58,59]. In contrast to ALAD, PBGD and URO3S, there is
no erythroid-specific promoter in the UROD gene [60]. The
level of UROD mRNA is markedly increased in erythroid
tissues but the molecular basis of erythroid-specific upregula-
tion has not been determined [61].
Mutations in the UROD gene are causative for the familial
form of porphyria cutanea tarda (PCT) [62,63]. Familial PCT is
inherited as an autosomal dominant trait but, as with other
dominant forms of porphyria, phenotypic expression occurs
only in some heterozygotes. The disorder is clinically charac-
terized by a photosensitive dermatosis, usually less severe than
in CEP. The photosensitivity is mediated by uroporphyrin whichis generated in the liver, circulates in plasma and is excreted in
the urine. UROD protein and enzymatic activity is approxi-
mately half normal in erythrocytes of affected individuals and
uroporphyrin does not accumulate. In the liver, UROD protein
levels are half normal but enzyme activity is 25% or less. This
finding strongly suggests that an inhibitor of UROD is generated
in the liver, a suggestion supported by animal models of PCT
[64–66]. The more common sporadic form of PCT is not
associated with URODmutations [67]. In sporadic PCT, UROD
protein levels in the liver are normal but, as with familial PCT,
enzyme activity is 25% or less, again suggesting the presence of
a UROD inhibitor. Hepatic iron overload is found in both forms
of PCT and iron depletion through phlebotomy therapy corrects
the phenotype [2,68]. Approximately 20% of patients with PCT
have proven to be homozygous for the C282Y mutation of the
hemochromatosis gene (HFE) [69]. There is no clear explanation
for the hepatic siderosis in the other 80% of cases. Several
environmental factors are associated with clinical expression of
PCT including alcohol abuse, hepatitis C and exposure to
medicinal estrogens [69].
In rare instances homozygosity or compound heterozygosity
for UROD mutations have been recognized and result in a
disease called hepatoerythropoietic porphyria (HEP). The
clinical manifestations are similar to PCT, but occur earlier in
life and are more severe [2]. Residual UROD activity has varied
widely, but is usually less than 10% of normal. Complete loss of
UROD activity is incompatible with life as homozygosity for a
null mutation in mice proved to be an embryonic lethal [66].
The next side chain modification is the sequential oxidative
decarboxylation of the propionate groups of pyrrole rings A and
B of COPRO'GEN III to form protoporphyrinogen IX
(PROTO'GEN IX). This reaction is catalyzed by coproporphyr-
inogen oxidase (CPO), an enzyme located in the mitochondrial
intermembrane space in mammals. There are both oxygen-
dependent and oxygen-independent forms of this enzyme,
termed hemN and hemF, respectively. Both enzymes decarbo-
xylate the A and B pyrrole ring propionates to vinyl groups.
Fig. 7. (A) Synthesis of coproporphyrinogen III (COPRO'GEN III). The reaction is catalyzed by the cytosolic enzyme uroporphyrinogen decarboxylase (UROD). The
enzyme sequentially decarboxylates the four acetate side chains of URO'GEN III (red) starting at the asymmetric D ring to generate the tetra-carboxylic, tetra-methyl
COPRO'GEN III. (B) Flexibility of the porphyrinogen substrate. The four pyrrole nitrogens (blue) of URO'GEN III form hydrogen bonds with asparagine 86 of
UROD. The porphyrinogen macrocycle assumes a domed configuration. Sufficient flexibility to form the domed configuration is a property of porphyrinogens and not
of the planar, more rigid porphyrins. Upper panel: front view. Lower panel: top view. Adapted from [57].
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dependent form which releases two molecules of CO2 and H2O2
(Fig. 8) [70]. It has been suggested that oxygen-dependent
CPO catalyzes an unusual metal- and cofactor-independent
oxidative decarboxylation in which molecular oxygen acts
as the immediate electron acceptor [71]. The protein pos-
sesses an unusually long leader sequence that is required for
mitochondrial localization [8]. Access of COPRO'GEN III tothe intermembrane space may be mediated by a peripheral-type
benzodiazepine receptor [72]. CPO in eukaryotes and some
prokaryotes is an oxygen-dependent enzyme [73]. The crystal
structures of both human and yeast oxygen-dependent CPO have
been determined [71, 74]. The enzyme functions as a homodimer
[73]. The structure of CPO permits the enzyme to maintain the
substrate as a porphyrinogen in the oxidative environment of the
mitochondrion, yet allows access of oxygen to the active site for
Fig. 8. Synthesis of protoporphyrinogen IX (PROTO'GEN IX). The reaction is catalyzed by the enzyme coproporphyrinogen oxidase (CPO) which resides in the
mitochondrial inner membrane space. The enzyme oxidizes the propionate groups (red) of the A and B rings of COPRO'GEN III to form the two vinyl groups (red) of
PROTO'GEN IX with the release of two molecules of CO2 and two molecules of H2O2.
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[74]. The human CPO gene has been cloned and is located on
chromosome 3q12 [75]. The promoter region encodes an Sp-
1-like element, a GATA site and a novel regulatory element that
interacts in a synergistic manner in erythroid cells [76]. In non-
erythroid tissue the GATA site is not necessary for transcription
but the novel regulatory element is required. There is differential
regulation of CPO with increased expression in erythroid cells, a
finding consistent with erythroid upregulation mediated by the
GATA site [77].
Mutations of the CPO gene are responsible for human
disorder hereditary coproporphyria (HCP). It has been sug-
gested that most of the disease-causing mutations destabilize the
enzyme [73,74]. HCP is characterized clinically by acute
neurovisceral attacks similar to those seen in patients with AIP
[19]. In contrast to AIP, photosensitivity may also be present.
The biochemical features of HCP include a marked increase in
urinary and fecal coproporphyrin content. As with AIP, urinaryFig. 9. Synthesis of protoporphyrin IX (PROTO IX). The reaction is catalyzed by pro
mitochondrial membrane. The six-electron oxidation to the planar macrocycle PROT
double bond structure of the macrocycle gives the porphyrin fluorescent properties.ALA and PGB are increased during the acute neurovisceral
attacks. Infusion of hematin is the recommended treatment for
acute attacks [19]. HCP is inherited as an autosomal dominant
trait but only some heterozygotes develop a clinical illness.
Rare, severe cases have been described in which both alleles of
CPO were mutant [78, 79].
PROTO'GEN IX is oxidized to protoporphyrin IX (PROTO
IX) by the enzyme protoporphyrinogen oxidase (PPO) (Fig. 9).
The six electron oxidation requires oxygen as the terminal
electron acceptor. The crystal structure of human PPO has been
determined and the enzyme functions as a homodimer [80].
Each homodimer contains one non-covalently bound FAD. The
enzyme is synthesized in the cytosol and transported to the outer
surface of the inner mitochondrial membrane. The protein
contains a mitochondrial targeting sequence between 151 and
175 residues from the N-terminus with a minor sequence within
the first 150 amino acids [81]. The human PPO gene is located
on chromosome 1q22–123 [82,83]. The 5′ flanking region oftoporphyrinogen oxidase (PPO) which is located on the outer surface of the inner
O IX requires oxygen as the terminal electron acceptor. The alternating single-
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suggesting the potential for erythroid-specific regulation.
When mouse erythroleukemia cells were induced with
dimethylsulfoxide, expression of the three terminal enzymes
in the heme biosynthetic pathway increased [83,84].
Mutations of PPO are responsible for variegate porphyria
(VP). More than 100 mutations of the PPO gene have been
identified and include missense, nonsense and splice site
mutations as well as deletions and insertions (Human Gene
Mutation Database) [85]. The disorder is transmitted as an
autosomal dominant trait. VP is seen in all racial groups but is
particularly common in South African whites (estimated
incidence 3 per thousand). A founder mutation in this
population has been traced to an immigrant in the 17th century
[2,86]. As with other acute porphyrias, most gene carriers do
not develop a clinical illness. VP is characterized clinically by
acute neurovisceral attacks, cutaneous photosensitivity or both.
Symptoms rarely occur before puberty. Genotype/phenotype
correlations have been unsatisfactory. The same mutation
present in two unrelated individuals may result in vastly
different clinical phenotypes [85]. Rare individuals with two
mutant PPO alleles and markedly reduced PPO activity
develop clinical manifestations in childhood [87,88]. Urinary
excretion of ALA and PBG is increased during acute attacks
but may be normal during periods of remission [19]. The fecal
content of protoporphyrin and coproporphyrin is markedly
increased. PPO activity is approximately half normal in all
tissues. A patient with VP demonstrated biochemical and
clinical improvement following liver transplant for alcoholic
cirrhosis [89]. This result, and the previously mentioned liver
transplant in a patient with AIP (see above), support the role of
overproduction of ALA and PBG by the liver as causative for
the neurovisceral attacks of acute porphyrias. In vitro
experiments indicated inhibition of PBGD by protoporphyr-
inogen and coproporphyrinogen possibly explaining the
accumulation of ALA and PBG in patients with VP [90].
Therapy with intravenous hematin is an effective method of
treating acute attacks [19].Fig. 10. Synthesis of heme. The final step in heme synthesis is catalyzed by the mito
one atom of ferrous iron (red) into the PROTO IX macrocycle.1.4. Insertion of iron into protoporphyrin IX
The final step in the heme biosynthetic pathway occurs on
the inner surface of the inner mitochondrial membrane where
iron is inserted into protoporphyrin IX (PROTO IX) by
ferrochelatase (FECH) (Fig. 10). Human FECH has been
crystallized and the enzyme functions as a homodimer [91]. It
has been suggested that a direct interaction occurs between PPO
on the outer surface of the inner mitochondrial membrane and
FECH which permits direct transfer of PROTO IX from PPO to
the active site of FECH [80], but experiments using isolated
mitochondria suggest that a complex between enzymes is not
required for heme synthesis [92]. Each monomer of FECH
contains a nitric oxide-sensitive 2Fe–2S cluster [93].
The human FECH gene has been cloned and mapped to
chromosome 18q21.3 [94]. The same transcriptional start site is
utilized in erythroid and non-erythroid cells and contains
potential binding sites for Sp1, NF-E2 and GATA1 [95]. A
region (−150) containing the Sp1 sites but lacking the erythroid-
specific cis elements was capable of inducing expression of a
luciferase reporter gene in erythroid cells [96]. It was later
shown that the 5′ flanking region of the FECH gene was both
necessary and sufficient to obtain transgene expression in
erythroid tissue [97]. FECH is synthesized in the cytosol and
targeted to mitochondria by sequences in the leader peptide. The
leader peptide is subsequently cleaved to produce the mature
form of the enzyme [98]. Expression of FECH is regulated by
intracellular iron levels, a finding presumably related to the
enzyme's requirement for an iron–sulfur cluster [99]. The
FECH gene is also regulated by hypoxia through interactions
with hypoxia inducible factor 1 [100].
Mutations of the FECH gene result in erythropoietic
protoporphyria (EPP). Early studies suggested that EPP is
transmitted as an autosomal dominant trait, but a large
pedigree study involving 200 patients and 91 families
indicated co-inheritance of a second defective FECH gene
from an unaffected parent was needed [101]. An allele
resulting in low level transcription activity has been confirmedchondrial enzyme ferrochelatase (FECH). The enzyme catalyzes the insertion of
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for morbidity [102,103]. Protoporphyrin accumulates mainly
in bone marrow reticulocytes, diffuses into plasma, is taken up
by the liver and excreted in the bile [2]. Protoporphyrin is
present in excess in the feces but is not excreted in the urine. In
a minority of patients, excess protoporphyrin in the bile leads
to cholestasis and cirrhosis [104]. Patients with EPP frequently
develop fluorescent gallstones containing large quantities of
protoporphyrin.
The dominant clinical feature of EPP is cutaneous
photosensitivity which usually begins in childhood. The
cutaneous manifestations differ from other porphyrias with
photosensitivity as bullous lesions are uncommon and severe
scarring is unusual. Instead, the skin develops a leathery
characteristic that mimics premature aging. No neurovisceral
attacks are associated with EPP. Nearly ninety FECH mutations
have been identified including missense, nonsense and splicing
deletions and small and large deletions and insertions (human
gene mutation database). Most patients with EPP have only 10–
25% of normal FECH activity rather than the 50% activity
expected in an autosomal dominant trait [2]. Because FECH is
active as dimer, it has been suggested that a mutant allele may
function in a dominant-negative fashion in which mutant
homodimers and mutant-wild type heterodimers are inactive.
Only wild type homodimers would be active. More recently,
however, it has been demonstrated that many patients exhibiting
the EPP phenotype have, in addition to a mutant FECH allele, a
common wild type FECH allelic variant resulting in low
expression [103].
Therapeutic measures for EPP include quenching of
porphyrin fluorescence by administering β-carotene, the
application of topical ointments which block long-range
ultraviolet light and the administration of cholestyramine [2].
Cholestyramine, a resin capable of binding protoporphyrin,
interrupts the enterohepatic recirculation of protoporphyrin and
promotes fecal excretion. In selected patients with protopor-
phyric liver disease, liver transplantation has been beneficial,
but the transplanted liver is susceptible to protoporphyrin-
induced damage [105]. A patient with EPP who developed
acute myeloblastic leukemia underwent bone marrow trans-
plantation [106]. This resulted in a dramatic biochemical and
clinical remission of the EPP. This case establishes that it is the
bone marrow, and not other tissues, that is responsible for the
clinical manifestations of EPP. It was recently demonstrated
that the overproduction of protoporphyrin due to mutations in
FECH can be severe enough to cause acute liver damage
[107].
2. Summary
Tissue-specific regulatory features characterize the heme
biosynthetic pathway. In non-erythroid cells the pathway is
regulated by heme-mediated feedback inhibition. In contrast, in
erythroid cells regulation is based on the availability of iron as
Fe/S clusters. The first four enzymes in the pathway are
regulated differently in erythroid and non-erythroid tissues,
either through tissue-specific genes (ALAS1 and ALAS2) orthrough single genes with tissue-specific promoter regions. In
eukaryotic cells the pathway is divided between mitochondrial
and cytosolic compartment (Fig. 1). Cytosolic enzymes utilize
unstable, reduced substrates but no data exist to support the
concept that enzyme complexes exist to facilitate transfer of the
product of one enzyme to the next enzyme in the pathway.
Models for the spatial relationship of enzymes involved in the
mitochondrial reactions have been proposed but existing data
support only a potential PPO–FECH interaction. The structure
of enzymes catalyzing the final four enzymatic steps are
remarkably diverse even though all utilize tetrapyrrole macro-
cycles as substrates. This structural diversity suggests that these
enzymes did not evolve through a mechanism of gene
duplication.
With the exception of ALAS1, human porphyric disorders
result from mutations in all of the heme biosynthetic enzymes.
The phenotypes of the porphyric disorders vary widely
depending upon whether porphyrin precursors, porphyrins or
both are present in excess.
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